Get notified when BBLG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Going Concern (new) — The company's auditor expressed substantial doubt about its ability to continue as a going concern due to recurring operating losses.
Bone Biologics launches up to $1.06M at-the-market offering; auditor flags going concern
Filed March 13, 2026 · ~1 min read
Key Changes
-
high
Bone Biologics is offering up to $1,064,000 of common stock via an at-the-market program with H.C. Wainwright, with no minimum amount required.
The Offering verify on EDGAR → -
high
The company incurred a GAAP net loss of $3.1 million in 2025 and used $2.7 million in operating cash, with cash runway only into Q4 2026.
Risk Factors verify on EDGAR → -
medium
Proceeds are intended for clinical trials, patent maintenance, and working capital, but actual net proceeds are uncertain due to the ATM structure.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade BBLG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify